LYON, France I November 14, 2024 I Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating ...

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...

I’m a big fan of its no-contract policy and senior-focused devices. Consumer Cellular’s wireless service is powered through several cellular networks, including AT&T. If you live in a rural area, ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

It doesn't happen instantly, so give it a good 15 seconds before ... If all else fails, try a signal booster to improve cell ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T cells -; which have lost their cancer-fighting oomph -; consume this lactic ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

Comprehensive coverage of the hexavalent vaccine can protect against whooping cough and polio, averting disease resurgence, writes Esther Nakkazi.

The Middlesex College Information Technology (IT) department is expanding wireless and cellular access, enhancing safety measurements and deploying technical devices during the fall semester to assist ...